Arrowhead Pharmaceuticals, Inc. (ARWR)

Several key events have impacted Arrowhead Pharmaceuticals' stock price in the past six months. The FDA approved REDEMPLO for familial chylomicronemia syndrome (FCS), marking Arrowhead's first commercial product launch, contributing to a substantial increase in the stock price. REDEMPLO also received regulatory approvals from Health Canada and the Chinese National Medical Products Administration, further expanding its market potential. Arrowhead reported its Q1 fiscal year 2026 results, posting a net income of $30.8 million, with revenue reaching $264 million, exceeding analyst estimates. Arrowhead strengthened its balance sheet with approximately $1.33 billion in gross proceeds from various transactions. Interim clinical data for obesity candidates ARO-INHBE and ARO-ALK7 showed encouraging results, positively influencing market sentiment. Analysts have maintained a "Moderate Buy" consensus rating with an average price target of $81.67.

Arrowhead Pharmaceuticals' revenue has historically been, and continues to be, significantly influenced by collaboration and licensing agreements, as well as milestone payments from its partners. The company's first commercial product, REDEMPLO, was launched in the U.S. in November 2025, and traditional demand seasonality is not a primary characteristic of Arrowhead's revenue streams at this stage. Revenue recognition is more dependent on the timing of regulatory approvals, clinical trial milestones, and the structure of its collaboration agreements.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative medicines that treat intractable diseases by silencing the genes that cause them, operating within the healthcare sector, specifically in the biotechnology and pharmaceutical preparations industries. The company leverages its proprietary Targeted RNAi Molecule (TRiM™) platform, which utilizes RNA interference (RNAi) to degrade messenger RNA (mRNA) and inhibit the production of disease-driving proteins. Key products and pipeline candidates include REDEMPLO (plozasiran) for familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (SHTG), Olpasiran (partnered with Amgen) for atherosclerotic cardiovascular disease (ASCVD), Fazirsiran (partnered with Takeda Pharmaceutical) for liver disease associated with Alpha-1 Antitrypsin Deficiency (AATD), ARO-INHBE and ARO-ALK7 for obesity and metabolic diseases, ARO-DimerPA for mixed hyperlipidemia and atherosclerotic cardiovascular disease, ARO-RAGE for various muco-obstructive and inflammatory pulmonary diseases, and Zodasiran (formerly ARO-ANG3) for homozygous familial hypercholesterolemia (HoFH) and cardiovascular disease.

Arrowhead Pharmaceuticals, Inc. is headquartered in Pasadena, California, U.S., with research and development activities primarily conducted at its facility in Madison, Wisconsin. REDEMPLO has been approved in the United States, Canada, and China, with anticipated launches in the EU and UK later in 2026.

Arrowhead Pharmaceuticals has generally maintained a positive brand reputation, primarily driven by significant scientific and commercial achievements. The FDA approval and successful initial launch of REDEMPLO for FCS in the U.S., along with international approvals in Canada and China, are major milestones. Positive interim clinical data for its obesity candidates and the advancement of its TRiM™ platform and CNS pipeline have further contributed to a favorable perception. Strategic collaborations with major pharmaceutical partners like Sarepta and Novartis also validate its technology and pipeline.

Arrowhead Pharmaceuticals, Inc. is largely controlled by institutional investors, with institutional ownership standing at approximately 77.44% to 92.83% of shares outstanding, while individual investors hold around 4.4% to 18.08%. Major institutional owners include BlackRock, Inc., The Vanguard Group, Inc., Avoro Capital Advisors LLC, State Street Global Advisors, Inc., FMR LLC, Slate Path Capital LP, and Geode Capital Management, LLC. Christopher Anzalone, the President and CEO, is also a significant individual owner.